The company's Procysbi is approved in the United States for the treatment of a rare metabolic disorder, while Quinsair is approved in Europe and Canada for the treatment of chronic pulmonary infections in adults with cystic fibrosis. Raptor's resulting share price crash looked overdone, but in hindsight it showed a market realization that the group had got as much out of Procysbi as it was going to (Latest failure makes Raptor more affordable, September 14, 2015). The Ireland-based drug developer stated Monday that the accord will strengthen its business in the U.s.and provide a platform to expand in Europe and other worldwide markets.
The most recent analyst actions consisted of Morgan Stanley initiating the stock on July 22. (NASDAQ:RPTP) generated $125 million in revenue.
We believe the Raptor acquisition is in line with Horizon's strategy of strengthening rare disease portfolio.
Consensus estimates from Thomson Reuters call for total sales of $131.8 million for 2016 and $158.16 million for 2017.
Share prices sometimes get a bounce to the upside when analysts reiterate coverage. A year ago the company Raptor received regulatory approval for the expanded use of Procysbi (cysteamine bitartrate), the company's delayed-release capsules used to treat children ages two to six with nephropathic cystinosis, a life-threatening metabolic lysosomal storage disorder that causes toxic accumulation of cystine in all cells, tissues, and organs in the body. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Mean recommendation on this stock is 2.30. Horizon Pharma had a negative net margin of 0.34% and a positive return on equity of 23.46%.
Raptor Pharmaceuticals Corp. (NASDAQ:RPTP)'s earnings per share growth ratio for the past 5 years was noted as 6.4% while revenue increase for the past 5 years was 0%.
Following the news, both companies' stocks surged.
"We are very disciplined and very critically focused on becoming a rare disease company", Walbert said by phone.
Horizon markets seven medicines through its orphan, primary care and specialty business units for the treatment of arthritis pain and rare diseases.